Evidence map›Paper›PMID 40112661›Full record

ArticleVaccine2025

Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022.

Zubairu Iliyasu, Abba Ahmed Danzomo, Visalakshi Jeyaseelan, Mustapha Modu Gofama, Patricia Eyanya Akintan, Olugbenga Oyewumi Akinrinoye, Umar Also, Hamisu Abdullahi, Kabir Yusuf Mawashi, Auwal Umar Gajida and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zubairu IliyasuAminu Kano Teaching Hospital, Kano, Nigeria.
Abba Ahmed DanzomoMcKing Consulting Corporation, GA, USA.
Visalakshi JeyaseelanPolio Eradication,WHO HQ, Geneva, Switzerland.
Mustapha Modu GofamaUniversity of Maiduguri Teaching Hospital, Maiduguri, Nigeria.
Patricia Eyanya AkintanLagos University Teaching Hospital, Lagos, Nigeria.
Olugbenga Oyewumi AkinrinoyeUniversity College Hospital, Ibadan, Nigeria.
Umar AlsoRasheeed Shekoni Specialist Hospital, Dutse, Nigeria.
Hamisu AbdullahiWHO AFRO, Brazzaville, the Democratic Republic of the Congo.
Kabir Yusuf MawashiNational Primary Health Care Develoment Agency, Abuja, Nigeria.
Auwal Umar GajidaAminu Kano Teaching Hospital, Kano, Nigeria.
Giovanna SifontesUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
Bernardo A MainouUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
Rocio Lopez CavestanyPolio Eradication,WHO HQ, Geneva, Switzerland.
Ondrej MachPolio Eradication,WHO HQ, Geneva, Switzerland.
Harish VermaPolio Eradication,WHO HQ, Geneva, Switzerland. Electronic address: vermah@who.int.

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40112661
PMCPMC12132045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.